Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome measurements in scleroderma: results from a delphi exercise.
Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR. Gazi H, et al. Among authors: moreland lw. J Rheumatol. 2007 Mar;34(3):501-9. Epub 2007 Feb 1. J Rheumatol. 2007. PMID: 17299843
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR. Clements PJ, et al. Among authors: moreland lw. Arthritis Rheum. 1999 Jun;42(6):1194-203. doi: 10.1002/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7. Arthritis Rheum. 1999. PMID: 10366112 Free article. Clinical Trial.
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, Weisman MD, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Wong WK. Clements PJ, et al. Semin Arthritis Rheum. 2004 Feb;33(4):249-63. doi: 10.1053/s0049-0172(03)00135-5. Semin Arthritis Rheum. 2004. PMID: 14978663 Clinical Trial.
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, Korn JH, Merkel PA, Rothfield N, Wigley FM, Moreland LW, Silver R, Steen VD, Weisman M, Mayes MD, Collier DH, Medsger TA Jr, Seibold JR; Relaxin Study Group; Scleroderma Clinical Trials Consortium. Khanna D, et al. Among authors: moreland lw. J Rheumatol. 2005 May;32(5):832-40. J Rheumatol. 2005. PMID: 15868618 Clinical Trial.
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Khanna D, et al. Among authors: moreland lw. Arthritis Rheum. 2009 Apr;60(4):1102-11. doi: 10.1002/art.24380. Arthritis Rheum. 2009. PMID: 19333948 Free PMC article. Clinical Trial.
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. DeMarco PJ, et al. Arthritis Rheum. 2002 Nov;46(11):2983-9. doi: 10.1002/art.10589. Arthritis Rheum. 2002. PMID: 12428241 Free article. Clinical Trial.
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial.
Furst DE, Clements PJ, Wong WK, Mayes MD, Wigley F, White B, Weisman M, Barr W, Moreland L, Martin R, Medsger TA Jr, Steen V, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Peter JB, Seibold JR. Furst DE, et al. Rheumatology (Oxford). 2001 Jun;40(6):615-22. doi: 10.1093/rheumatology/40.6.615. Rheumatology (Oxford). 2001. PMID: 11426017 Clinical Trial.
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ. Khanna D, et al. Ann Rheum Dis. 2006 Oct;65(10):1325-9. doi: 10.1136/ard.2005.050187. Epub 2006 Mar 15. Ann Rheum Dis. 2006. PMID: 16540546 Free PMC article. Clinical Trial.
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Seibold JR. Clements PJ, et al. Arthritis Rheum. 2001 Mar;44(3):653-61. doi: 10.1002/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q. Arthritis Rheum. 2001. PMID: 11263780 Free article. Clinical Trial.
336 results